CVS RSI Chart
Last 7 days
-3.6%
Last 30 days
-11.6%
Last 90 days
-7.2%
Trailing 12 Months
-9.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 330.9B | 339.2B | 347.8B | 357.8B |
2022 | 299.8B | 307.9B | 315.2B | 322.5B |
2021 | 271.0B | 278.3B | 285.1B | 292.1B |
2020 | 261.9B | 263.8B | 266.0B | 268.7B |
2019 | 210.5B | 227.0B | 244.3B | 256.8B |
2018 | 186.0B | 187.2B | 188.5B | 194.6B |
2017 | 178.8B | 180.8B | 182.4B | 184.8B |
2016 | 160.2B | 166.7B | 172.7B | 177.5B |
2015 | 143.0B | 145.6B | 149.2B | 153.3B |
2014 | 128.7B | 132.1B | 135.1B | 139.4B |
2013 | 123.1B | 123.6B | 125.3B | 126.8B |
2012 | 112.2B | 116.5B | 120.0B | 123.1B |
2011 | 97.9B | 100.4B | 103.4B | 107.1B |
2010 | 98.9B | 97.9B | 97.0B | 95.8B |
2009 | 89.5B | 93.3B | 97.0B | 98.7B |
2008 | 0 | 80.0B | 83.8B | 87.5B |
2007 | 0 | 0 | 0 | 76.3B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | lynch karen s | acquired | 3,599,930 | 79.56 | 45,248 | president and ceo |
Apr 01, 2024 | cowhey thomas f. | acquired | - | - | 15,082 | evp and cfo |
Apr 01, 2024 | lynch karen s | sold (taxes) | -4,928,980 | 79.56 | -61,953 | president and ceo |
Apr 01, 2024 | joyner j. david | acquired | - | - | 28,280 | evp&president-pharmacyservices |
Apr 01, 2024 | khichi samrat s. | acquired | - | - | 12,569 | evp, cpo and general counsel |
Apr 01, 2024 | cowhey thomas f. | sold (taxes) | -136,764 | 79.56 | -1,719 | evp and cfo |
Apr 01, 2024 | havanec laurie p. | sold (taxes) | -607,043 | 79.56 | -7,630 | evp and chief people officer |
Apr 01, 2024 | kane brian a | acquired | - | - | 12,569 | evp/president, aetna |
Apr 01, 2024 | chaguturu sreekanth k | sold (taxes) | -182,829 | 79.56 | -2,298 | evp and chief medical officer |
Apr 01, 2024 | clark james david | acquired | 849,940 | 79.56 | 10,683 | svp, cont & chief acct officer |
Which funds bought or sold CVS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 16, 2024 | TSFG, LLC | reduced | -6.49 | -87,000 | 1,491,000 | 0.38% |
Apr 16, 2024 | KRS Capital Management, LLC | reduced | -14.64 | -32,246 | 201,796 | 0.16% |
Apr 16, 2024 | Shulman DeMeo Asset Management LLC | added | 0.11 | 2,386 | 219,381 | 0.06% |
Apr 16, 2024 | COURIER CAPITAL LLC | reduced | -1.11 | -7,353 | 6,993,140 | 0.51% |
Apr 16, 2024 | Powell Investment Advisors, LLC | unchanged | - | 2,109 | 210,327 | 0.11% |
Apr 16, 2024 | Asset Dedication, LLC | added | 3.38 | 88,000 | 1,952,000 | 0.15% |
Apr 16, 2024 | Moisand Fitzgerald Tamayo, LLC | unchanged | - | 84.00 | 8,375 | -% |
Apr 16, 2024 | Atwater Malick LLC | reduced | -2.26 | -83,574 | 6,484,740 | 2.29% |
Apr 16, 2024 | Lauer Wealth, LLC | reduced | -1.05 | -43,909 | 615,177 | 0.53% |
Apr 16, 2024 | Indiana Trust & Investment Management CO | reduced | -38.51 | -208,189 | 341,373 | 0.14% |
Unveiling CVS Health Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to CVS Health Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 441.4B | 371.6B | 19.72 | 1.19 | ||||
CI | 101.2B | 195.3B | 18.83 | 0.52 | ||||
CVS | 86.3B | 357.8B | 10.33 | 0.24 | ||||
HCA | 82.3B | 65.0B | 15.7 | 1.27 | ||||
CNC | 38.5B | 154.0B | 14.25 | 0.25 | ||||
DVA | 11.2B | 12.1B | 16.19 | 0.92 | ||||
UHS | 11.1B | 14.3B | 15.45 | 0.78 | ||||
MID-CAP | ||||||||
CHE | 9.1B | 2.3B | 33.52 | 4.03 | ||||
ACHC | 6.5B | 2.9B | -299.22 | 2.21 | ||||
AMN | 2.1B | 3.8B | 10.13 | 0.56 | ||||
AMEH | 2.1B | 1.4B | 34.15 | 1.5 | ||||
SMALL-CAP | ||||||||
ADUS | 1.6B | 1.1B | 25.08 | 1.48 | ||||
BKD | 1.2B | 3.0B | -6.47 | 0.41 | ||||
BEAT | 56.9M | - | -3.88 | - | ||||
AMS | 18.9M | 21.3M | 35.51 | 0.89 |
CVS Health Corp News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 4.5% | 93,813 | 89,764 | 88,921 | 85,278 | 83,846 | 81,159 | 80,636 | 76,826 | 76,604 | 73,794 | 72,616 | 69,097 | 69,554 | 67,056 | 65,341 | 66,755 | 66,889 | 64,810 | 63,431 | 61,646 | 54,424 |
Costs and Expenses | 5.1% | 90,440 | 86,074 | 85,687 | 81,832 | 80,187 | 85,078 | 75,967 | 73,281 | 74,258 | 70,733 | 68,290 | 65,520 | 67,030 | 63,807 | 60,661 | 63,297 | 63,852 | 61,882 | 60,099 | 58,956 | 53,600 |
Operating Expenses | - | - | - | - | - | - | - | 9,171 | 9,876 | - | - | 8,869 | 8,922 | - | 8,471 | 8,668 | 8,563 | 8,654 | 8,595 | 8,042 | 8,250 | 6,613 |
EBITDA Margin | -3.9% | 0.05* | 0.05* | 0.03* | 0.04* | 0.04* | 0.03* | 0.06* | 0.06* | 0.06* | 0.06* | 0.06* | 0.06* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -0.4% | 690 | 693 | 686 | 589 | 552 | 566 | 583 | 586 | 608 | 602 | 636 | 657 | 678 | 731 | 765 | 733 | 734 | 747 | 772 | 782 | 733 |
Income Taxes | -12.7% | 658 | 754 | 656 | 737 | 818 | -1,045 | 1,090 | 646 | 300 | 558 | 944 | 746 | 241 | 587 | 974 | 767 | 590 | 604 | 660 | 512 | 524 |
Earnings Before Taxes | -10.4% | 2,705 | 3,019 | 2,570 | 2,879 | 3,150 | -4,444 | 4,129 | 3,001 | 1,687 | 2,145 | 3,735 | 2,970 | 1,225 | 1,806 | 3,960 | 2,779 | 2,334 | 2,133 | 2,591 | 1,939 | 102 |
EBT Margin | -6.5% | 0.03* | 0.03* | 0.01* | 0.02* | 0.02* | 0.01* | 0.04* | 0.04* | 0.04* | 0.04* | 0.03* | 0.04* | - | - | - | - | - | - | - | - | - |
Net Income | -9.9% | 2,037 | 2,261 | 1,914 | 2,142 | 2,329 | -3,406 | 3,039 | 2,355 | 1,393 | 1,598 | 2,791 | 2,224 | 965 | 1,224 | 2,986 | 2,012 | 1,747 | 1,530 | 1,936 | 1,421 | -419 |
Net Income Margin | -6.1% | 0.02* | 0.02* | 0.01* | 0.01* | 0.01* | 0.01* | 0.03* | 0.03* | 0.03* | 0.03* | 0.03* | 0.03* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -263.4% | -3,547 | 2,171 | 5,317 | 6,454 | -2,640 | 8,543 | 5,035 | 2,512 | 3,408 | 4,913 | 5,361 | 2,063 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -0.6% | 249,728 | 251,306 | 250,071 | 239,330 | 228,275 | 231,212 | 230,279 | 232,873 | 233,052 | 234,891 | 231,164 | 229,606 | 230,715 | 232,898 | 235,495 | 230,639 | 222,449 | 220,113 | 218,904 | 219,768 | 196,456 |
Current Assets | -3.3% | 67,858 | 70,143 | 67,756 | 68,706 | 65,633 | 68,341 | 62,142 | 61,483 | 60,035 | 60,842 | 56,559 | 55,719 | 56,369 | 59,211 | 62,506 | 58,958 | 50,302 | 48,185 | 46,901 | 47,857 | 45,243 |
Cash Equivalents | -37.2% | 8,196 | 13,043 | 13,807 | 14,618 | 12,945 | 17,563 | 12,463 | 11,611 | 9,408 | 9,826 | 7,119 | 5,598 | 11,043 | 9,532 | 15,145 | 10,337 | 8,408 | 5,469 | 6,338 | 6,168 | 6,553 |
Inventory | 0.4% | 18,025 | 17,954 | 17,291 | 18,263 | 19,090 | 18,058 | 17,375 | 18,160 | 17,760 | 17,399 | 16,979 | 17,618 | 18,496 | 17,478 | 16,519 | 16,976 | 17,516 | 16,028 | 15,511 | 15,448 | 16,450 |
Net PPE | -100.0% | - | 13,022 | 13,001 | 12,872 | 12,873 | 12,626 | 12,764 | 12,844 | 12,896 | 12,771 | 12,664 | 12,611 | 12,606 | 12,349 | 12,221 | 12,146 | 12,044 | 11,651 | 11,483 | 11,348 | 11,349 |
Goodwill | 0.0% | 91,272 | 91,261 | 91,260 | 5,909 | 78,150 | 78,086 | 78,560 | 79,060 | 79,121 | 79,121 | 79,552 | 79,552 | 79,552 | 79,579 | 80,057 | 79,993 | 79,749 | 79,548 | 79,485 | 79,075 | 78,678 |
Liabilities | -2.1% | 173,092 | 176,796 | 177,069 | 167,750 | 156,506 | 160,201 | 154,773 | 158,733 | 158,211 | 160,273 | 157,599 | 158,442 | 161,014 | 163,786 | 167,140 | 165,165 | 158,279 | 157,180 | 157,305 | 159,762 | 137,913 |
Current Liabilities | -2.9% | 79,189 | 81,553 | 79,206 | 75,054 | 69,421 | 72,409 | 68,457 | 69,780 | 67,719 | 64,709 | 59,311 | 60,104 | 62,017 | 62,044 | 63,694 | 59,560 | 53,303 | 52,544 | 49,376 | 50,631 | 44,009 |
Short Term Borrowings | - | 200 | - | 1,000 | - | - | - | - | - | - | - | - | 252 | - | - | - | 255 | - | 1,070 | 446 | 3,005 | 720 |
Long Term Debt | -1.9% | 58,638 | 59,782 | 61,419 | 56,450 | 50,476 | 50,848 | 50,797 | 52,063 | 51,971 | 56,832 | 59,294 | 59,270 | 59,207 | 61,552 | 63,481 | 65,735 | 64,699 | 64,206 | 66,941 | 67,888 | 71,444 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8,192 | 5,828 | 3,781 | 3,778 | 3,894 | 3,893 | 1,265 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63,481 | 65,735 | 64,699 | 64,206 | 66,941 | 67,888 | 71,444 |
Shareholder's Equity | 2.9% | 76,461 | 74,337 | 73,002 | 71,580 | 71,469 | 71,487 | 75,736 | 74,034 | 74,841 | 74,618 | 73,565 | 71,164 | 69,701 | 69,112 | 68,355 | 65,474 | 64,170 | 62,933 | 61,599 | 60,006 | 58,543 |
Retained Earnings | 2.1% | 61,604 | 60,343 | 58,868 | 57,753 | 56,398 | 54,571 | 58,710 | 56,488 | 54,997 | 54,264 | 53,331 | 51,203 | 49,640 | 49,328 | 48,768 | 46,455 | 45,108 | 44,017 | 43,136 | 41,859 | 40,911 |
Shares Outstanding | 0.1% | 1,288 | 1,287 | 1,282 | 1,279 | 1,300 | 1,313 | 1,313 | 1,312 | 1,319 | 1,318 | 1,316 | 1,313 | - | - | - | - | - | - | - | - | - |
Minority Interest | 1.2% | 175 | 173 | 276 | 198 | 300 | 328 | 322 | 310 | 306 | 310 | 321 | 314 | 312 | 305 | 333 | 334 | 306 | 319 | 317 | 320 | 318 |
Float | - | - | - | 88,548 | - | - | - | 121,258 | - | - | - | 109,651 | - | - | - | 84,719 | - | - | - | 70,618 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -197.1% | -2,636 | 2,716 | 5,908 | 7,438 | -1,952 | 9,123 | 5,443 | 3,563 | 4,005 | 5,521 | 5,847 | 2,892 | 3,567 | 1,874 | 7,119 | 3,305 | 2,634 | 2,928 | 5,338 | 1,948 | 2,479 |
Share Based Compensation | -17.5% | 127 | 154 | 204 | 103 | 106 | 105 | 147 | 89.00 | 138 | 114 | 145 | 87.00 | 112 | 109 | 83.00 | 96.00 | 98.00 | 129 | 112 | 114 | 108 |
Cashflow From Investing | -61.1% | -1,242 | -771 | -10,362 | -8,514 | -119 | -805 | -2,130 | -1,993 | -1,440 | -847 | -1,107 | -1,867 | -1,234 | -1,370 | -1,333 | -1,597 | -709 | -829 | -910 | -891 | -41,899 |
Cashflow From Financing | 64.0% | -972 | -2,697 | 3,626 | 2,726 | -2,187 | -3,218 | -2,461 | -2,650 | -2,914 | -1,930 | -3,327 | -3,185 | -3,276 | -6,117 | -978 | 2,675 | -1,244 | -2,968 | -4,258 | 816 | 1,892 |
Dividend Payments | 0% | 779 | 779 | 795 | 779 | 719 | 726 | 740 | 722 | 660 | 659 | 650 | 656 | 644 | 665 | 663 | 652 | 651 | 646 | 657 | 649 | 510 |
Buy Backs | 66.7% | -1.00 | -3.00 | -2.00 | 2,018 | 1,500 | - | - | 2,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Premiums | $ 99,192 | $ 85,330 | $ 76,132 |
Net investment income | 1,153 | 838 | 1,199 |
Total revenues | 357,776 | 322,467 | 292,111 |
Operating costs: | |||
Cost of products sold | 217,098 | 196,892 | 175,803 |
Health care costs | 86,247 | 71,073 | 64,188 |
Restructuring charges | 507 | 0 | 0 |
Opioid litigation charges | 0 | 5,803 | 0 |
Loss on assets held for sale | 349 | 2,533 | 0 |
Store impairments | 0 | 0 | 1,358 |
Goodwill impairment | 0 | 0 | 431 |
Operating expenses | 39,832 | 38,212 | 37,021 |
Total operating costs | 344,033 | 314,513 | 278,801 |
Operating income | 13,743 | 7,954 | 13,310 |
Interest expense | 2,658 | 2,287 | 2,503 |
Loss on early extinguishment of debt | 0 | 0 | 452 |
Other income | (88) | (169) | (182) |
Income before income tax provision | 11,173 | 5,836 | 10,537 |
Income tax provision | 2,805 | 1,509 | 2,548 |
Net income | 8,368 | 4,327 | 7,989 |
Net (income) loss attributable to noncontrolling interests | (24) | (16) | 12 |
Net income attributable to CVS Health | $ 8,344 | $ 4,311 | $ 8,001 |
Net income per share attributable to CVS Health: | |||
Basic (in dollars per share) | $ 6.49 | $ 3.29 | $ 6.07 |
Diluted (in dollars per share) | $ 6.47 | $ 3.26 | $ 6.02 |
Weighted average shares outstanding: | |||
Basic (in shares) | 1,285 | 1,312 | 1,319 |
Diluted (in shares) | 1,290 | 1,323 | 1,329 |
Dividends declared per share (in dollars per share) | $ 2.42 | $ 2.20 | $ 2.00 |
Cost, Product and Service [Extensible List] | Products | Products | Products |
Products | |||
Revenues: | |||
Revenues | $ 245,138 | $ 226,616 | $ 203,738 |
Services | |||
Revenues: | |||
Revenues | $ 12,293 | $ 9,683 | $ 11,042 |
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Assets: | ||
Cash and cash equivalents | $ 8,196 | $ 12,945 |
Investments | 3,259 | 2,778 |
Accounts receivable, net | 35,227 | 27,276 |
Inventories | 18,025 | 19,090 |
Assets held for sale | 0 | 908 |
Other current assets | 3,151 | 2,636 |
Total current assets | 67,858 | 65,633 |
Long-term investments | 23,019 | 21,096 |
Property and equipment, net | 13,183 | 12,873 |
Operating lease right-of-use assets | 17,252 | 17,872 |
Goodwill | 91,272 | 78,150 |
Intangible assets, net | 29,234 | 24,803 |
Separate accounts assets | 3,250 | 3,228 |
Other assets | 4,660 | 4,620 |
Total assets | 249,728 | 228,275 |
Liabilities: | ||
Accounts payable | 14,897 | 14,838 |
Pharmacy claims and discounts payable | 22,874 | 19,423 |
Health care costs payable | 12,049 | |
Health care costs payable | 10,142 | |
Policyholders’ funds | 1,326 | 1,500 |
Accrued expenses | 22,189 | 18,745 |
Other insurance liabilities | 1,141 | 1,089 |
Current portion of operating lease liabilities | 1,741 | 1,678 |
Short-term debt | 200 | 0 |
Current portion of long-term debt | 2,772 | 1,778 |
Liabilities held for sale | 0 | 228 |
Total current liabilities | 79,189 | 69,421 |
Long-term operating lease liabilities | 16,034 | 16,800 |
Long-term debt | 58,638 | 50,476 |
Deferred income taxes | 4,311 | 4,016 |
Separate accounts liabilities | 3,250 | 3,228 |
Other long-term insurance liabilities | 5,459 | 5,835 |
Other long-term liabilities | 6,211 | 6,730 |
Total liabilities | 173,092 | 156,506 |
Commitments and contingencies (Note 18) | ||
Shareholders’ equity: | ||
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding | 0 | 0 |
Common stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at December 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital surplus | 48,992 | 48,193 |
Treasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 | (33,838) | (31,858) |
Retained earnings | 61,604 | 56,398 |
Accumulated other comprehensive loss | (297) | (1,264) |
Total CVS Health shareholders’ equity | 76,461 | 71,469 |
Noncontrolling interests | 175 | 300 |
Total shareholders’ equity | 76,636 | 71,769 |
Total liabilities and shareholders’ equity | $ 249,728 | $ 228,275 |